Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months. This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio s genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma.
Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92% of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months.
Shortly before her 34th birthday, King was diagnosed with a grade 2 astrocytoma tumor in her right temporal lobe, and it could not be removed without cutting out part of her brain. Thanks to a clinical trial at UAB, her.
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Birmingham’s Pepper Place has a striking new addition to its teeming farmers’ market and noted food offerings a multimillion-dollar cancer research laboratory. The lab is IN8bio’s new research and development facility in the Martin Biscuit Building